J&J Acquires Experimental Eczema Drug in $1.25 Billion Cash Deal [BNN Bloomberg (Canada)]
Kenvue Inc. (KVUE)
Company Research
Source: BNN Bloomberg
In the all-cash deal, J&J will acquire NM26, a bispecific antibody that privately held Numab Therapeutics is preparing to put into mid-stage human studies, according to a statement Tuesday. The therapy targets two proteins that cause the itchiness and inflammation of eczema, also known as atopic dermatitis. J&J is among a host of pharmaceutical companies investing in bispecific antibodies, which have become standard treatments for certain cancers and are emerging as viable medicines for more common diseases. The drug giant is on the lookout for new products after separating from its consumer health division, now called Kenvue Inc., to focus on innovative medicines and devices. The deal with Switzerland-based Numab adds to J&J's inflammatory-disease portfolio, led by the blockbuster psoriasis treatment Tremfya, and investigational treatments for inflammatory bowel disease, lupus and rheumatoid arthritis. Numab's drug may also treat other conditions that involving itching and infla
Show less
Read more
Impact Snapshot
Event Time:
KVUE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KVUE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KVUE alerts
High impacting Kenvue Inc. news events
Weekly update
A roundup of the hottest topics
KVUE
News
- Kenvue Inc. (NYSE: KVUE) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $27.00 price target on the stock.MarketBeat
- Kenvue Inc. (NYSE: KVUE) was downgraded by analysts at Royal Bank of Canada from an "outperform" rating to a "sector perform" rating. They now have a $24.00 price target on the stock.MarketBeat
- Kenvue Inc. (NYSE: KVUE) had its price target raised by analysts at Piper Sandler from $20.00 to $21.00. They now have a "neutral" rating on the stock.MarketBeat
- Kenvue Drives Climate Action Strategy Forward [Yahoo! Finance]Yahoo! Finance
- Kenvue Drives Climate Action Strategy ForwardBusiness Wire
KVUE
Earnings
- 8/6/24 - Beat
KVUE
Sec Filings
- 9/19/24 - Form 4
- 9/10/24 - Form SC
- 8/16/24 - Form 3
- KVUE's page on the SEC website